---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-002"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-002. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 29 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/bond-002"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-002

<a id="heading-3.1.4"></a>

## 3.1.4 BOND-002

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registered study purpose

> “To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.1-2"></a>

#### Objective of the interim analysis

> “We evaluated interim results of a phase II trial for intravesical CG0070 in patients with BCG-unresponsive NMIBC who refused cystectomy.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-06-02” |
| Primary completion (actual) | “2018-08” |
| Study completion (actual) | “2019-02” |
| Number of sites | “This study has 17 locations” |
| Principal investigator | “Gary Steinberg, MD” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.2-2"></a>

#### Interim analysis date

> “At interim analysis (April 2017)”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Registered design: open-label, single-arm, phase 2

> “An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG (Bacillus Calmette-Guerin) Therapy and Refused Cystectomy”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.3-2"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.3-3"></a>

#### Company description of the design and population

> “The BOND-002 trial was a Phase 2, open-label, single-arm clinical trial of cretostimogene in patients with high-risk NMIBC after BCG failure.”
> “The trial included a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Inclusion: high-grade NMIBC after prior intravesical therapy including BCG

> “Patients must have pathologically confirmed non-muscle invasive bladder cancer (NMIBC) high grade disease (HG), as defined by the 2004 WHO classification system”
> “Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. Bacillus Calmette-Guerin (BCG) must have been one of the prior therapies administered.”
> “Patients can have either failed BCG induction therapy within a six-month period or have been successfully treated with BCG, but subsequently found to have recurrence. The first standard course of intravesical BCG therapy must include at least six weekly treatments (allowable range of instillations per course is 4-9). The second course of BCG therapy must include at least two weekly treatments.”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-2"></a>

#### Inclusion: carcinoma in situ, or recurrent Ta or T1 disease

> “Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the past. For those patients with only Ta or T1 disease at enrollment AND with no history of Cis, they must have”
> “disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR”
> “disease recurrence within 18 months of BCG maintenance OR”
> “disease recurrence within 24 months of BCG induction”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-3"></a>

#### Inclusion: cystectomy declined, age, and performance status

> “Radical cystectomy has been declined by the patient in a signed special section of the informed consent, whereby there is a clear explanation by the investigator to the subject that a delay of cystectomy may increase his/her chance of disease progression, the results of which may lead to serious and life threatening consequences.”
> “18 years of age or older”
> “Eastern Cooperative Oncology Group (ECOG) performance status <2.”
> “Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-4"></a>

#### Exclusion criteria

> “Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable”
> “Known infection with HIV, HBV or HCV.”
> “Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted).”
> “History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-5"></a>

#### Prior therapy of the interim population

> “All patients received at least 2 prior courses of intravesical therapy for CIS, with at least 1 being a course of BCG.”
> “Patients had either failed BCG induction therapy within 6 months or had been successfully treated with BCG with subsequent recurrence.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Registered regimen

> “Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.”
> “oncolytic adenovirus with a E2F promotor and expresses GMCSF”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.5-2"></a>

#### Company description of dose, induction, and maintenance

> “Cretostimogene was administered intravesically at 1x1012 viral particles (VPs) per milliliter to patients who had refused radical cystectomy”
> “Patients received an initial induction course of six weekly administrations.”
> “Patients who achieved a CR at month six received six weekly maintenance doses of cretostimogene using the same concentration.”
> “Patients whose disease did not respond to the first induction course received accelerated maintenance at month three to four, which involved early administration of the maintenance normally provided at six months.”
> “Six weekly follow up doses were then administered at months 12 and 18.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Durable Complete Response at 18 Months as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registered primary endpoint: durable complete response proportion

> “Durable Complete Response Proportion (DCR)”
> “Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention”
> “18 months time point from the date of the first intravesical intervention”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.6.1-2"></a>

##### Registered secondary endpoints

> “Cystectomy Free Survival”
> “Progression Free Survival”
> “Time to Progression to Muscle Invasive Disease”
> “PD-L1 status of cancer cells and immune cells at tumor site by IHC”
> “Proportions of patients with a complete response of at least 12 months' duration”
> “Proportions of patients with a partial response and/or a complete response of less than 12 months' duration”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.6.1-3"></a>

##### Endpoint reported in the interim analysis: complete response at 6 months

> “Complete response (CR) at 6 months was defined as absence of disease on cytology, cystoscopy, and random biopsies.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.6.1-4"></a>

##### Regulatory context for durable complete response in single-arm trials

> “attainment of a durable CR may represent clinical benefit by allowing some patients to delay or”
> “forgo radical cystectomy.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “66” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants enrolled, by disease group

> “A total of 65 patients were enrolled, which included 46 CIS patients, with or without Ta/T1 disease, and 19 patients with Ta/T1 disease.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Interim efficacy set: participants with 6-month follow-up

> “At interim analysis (April 2017), 45 patients with residual high-grade Ta, T1, or carcinoma-in-situ (CIS) ± Ta/T1 had evaluable 6-month follow-up in this phase II single-arm multicenter trial”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.7.2-2"></a>

##### Safety set: protocol participants and three additional treated patients

> “In addition to the 65 patients enrolled per the trial protocol, the safety results above included three additional patients, two who were dosed with cretostimogene for compassionate, single-use patient INDs and one more determined not to have baseline NMIBC retrospectively.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Tumor stage at entry in the interim population

> “Of 45 patients, there were 24 pure CIS, 8 CIS + Ta, 4 CIS + T1, 6 Ta, 3 T1.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Complete response at 6 months: interim analysis

> “Overall 6-month CR (95% CI) was 47% (32%-62%).”
> “Considering 6-month CR for pathologic subsets, pure CIS was 58% (37%-78%), CIS ± Ta/T1 50% (33%-67%), and pure Ta/T1 33% (8%-70%).”
> “At 6 months, the single patient that progressed to muscle-invasive disease had Ta and T1 tumors at baseline.”
> “No patients with pure T1 had 6-month CR.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.8.3-2"></a>

##### Complete response at any time and duration of response: company report

> “Among the 40 (61.5%) patients achieving a CR at any timepoint, the median DOR had yet to be reached after 18 months, with 21 patients (52.5%) without disease progression at 18 months.”
> “Specifically in the 46 patients with high-risk CIS-containing NMIBC, 30 (65.2%; 95% CI, 49.7-78.2%) patients displayed a CR at any time subsequent to administration of cretostimogene.”
> “Four out of 10 (40.0%) patients who did not achieve CR at three months, and who were subsequently re-dosed with cretostimogene at three months demonstrated CR at six months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.4.8.3-3"></a>

##### Complete response at 6 and 12 months in CIS-containing disease: company report

> “Among the 46 patients with high-risk CIS-containing NMIBC, 30 (65%; 95% CI: 50-78%) patients displayed a CR at any time subsequent to administration of cretostimogene.”
> “44% and 28% of patients demonstrating a CR at six months and 12 months, respectively”

Source: [CG Oncology prospectus (2024)](https://www.sec.gov/Archives/edgar/data/1991792/000119312524015534/d551455d424b4.htm)

Additional sources: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf); [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Treatment-related adverse events at 6 months: interim analysis

> “Treatment-related adverse events (AEs) at 6 months were most commonly urinary bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%).”
> “Immunologic treatment-related AEs included flu-like symptoms (12%) and fatigue (6%).”
> “Grade III treatment-related AEs included dysuria (3%) and hypotension (1.5%). There were no Grade IV/V treatment-related AEs.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.8.5-2"></a>

##### Treatment-related and serious adverse events: company report

> “Cretostimogene was generally well-tolerated and most TRAEs were limited to Grade 1 to 2, only two Grade 3 TRAEs involving dysuria and hypotension (both of which were resolved), and no Grade 4 or 5 TRAEs.”
> “Furthermore, eight serious adverse events (SAEs) were reported but were determined not related to cretostimogene.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary: limitations of BOND-002

- Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
- Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
- Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
- Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
- Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
- No results posted on ClinicalTrials.gov were identified.

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818); [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
